Patients who have undergone pelvic radiotherapy may live with low-grade chronic inflammation of the lower intestine 20 years after the treatment. 0
Santhera’s Agamree becomes first approved treatment in UK for all DMD patients – Pharmaceutical Technology
Share this article Santhera’s chief medical officer Shabir Hasham said the company is planning on making Agamree available in the UK in the second half